Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

1885studies indexed841with human data111registered trials1630carry a numeric findingLibrarian added 33 studies today
Showing 841 studiesSortNewest indexed
B
grade
Real-world outcomes of [<sup>177</sup>Lu]Lu-PSMA-I&T in [<sup>18</sup>F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survival.
Vipivotide · European journal of nuclear medicine and molecular imaging · 2026 · Observational · n=25
Higher [68Ga]Ga-PSMA-11 SUVmean and SUVmean ratio may predict PSA response in [18F]FDG-positive mCRPC patients, but further research is needed.
PSA30 response in 44% of patients.
B
grade
Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T therapy: dosimetry results.
Vipivotide · European journal of nuclear medicine and molecular imaging · 2026 · Observational · n=50
ARSi did not significantly enhance tumor absorbed doses in mCRPC patients receiving [177Lu]Lu-PSMA therapies. Larger studies are needed to confirm these findings.
2.1 ± 4.0 Gy/GBq vs 1.5 ± 1.7 Gy/GBq for [177Lu]Lu-PSMA-617, p=0.24
B
grade
Evaluation of [<sup>225</sup>Ac]Ac-PSMA-617 vis-a-vis Rechallenge [<sup>177</sup>Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.
Vipivotide · The Prostate · 2026 · Observational · n=66
[225Ac]Ac-PSMA-617 shows promise for mCRPC with better survival and manageable toxicity, but further trials are needed.
PSA decline of >50% and disease control rate of 60% in [225Ac]Ac-PSMA-617 patients.
B
grade
Correlation of the estimated glucose disposal rate with self-reported endometrial cancer: a cross-sectional study from NHANES 1999-2018.
MGF (Mechano Growth Factor) · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2026 · Observational · n=31666High-impact journal
Higher estimated glucose disposal rate is associated with lower odds of self-reported endometrial cancer, suggesting a potential link between insulin sensitivity and cancer risk.
Odds ratio for eGDR inversely associated with self-reported EC was 0.906 (95% CI: 0.826-0.991, P = 0.0328)
A
grade
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.
Mazdutide (IBI362) · Lancet (London, England) · 2026 · RCT · Phase 3Top journal
Belzutifan plus lenvatinib showed a significant improvement in progression-free survival compared to cabozantinib, but overall survival did not reach statistical significance.
Median progression-free survival 14.8 months (95% CI 11.2-16.6) for belzutifan-lenvatinib vs 10.7 months (95% CI 9.2-11.1) for cabozantinib; HR 0.70, one-sided p<0.0001.
B
grade
Expression and Correlation Analysis of Neuropeptide Family Members in the Peripheral Blood of Patients with COVID-19.
VIP (Vasoactive Intestinal Polypeptide) · Current pediatric reviews · 2026 · Observational
ASCL1 levels are lower in children with COVID-19 compared to those with non-COVID-19 bronchial pneumonia, and it correlates negatively with inflammation markers like neutrophils and CRP.
ACE2 in non-COVID-19 and moderate COVID-19 groups was higher than that in severe groups (p=0.04; p=0.03, respectively).
A
grade
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
Tesamorelin · The Journal of clinical endocrinology and metabolism · 2010 · RCTHigh-impact journal
Tesamorelin significantly reduces visceral fat and improves lipid levels in HIV patients, but the long-term clinical implications of these changes are not fully understood.
-24 +/- 41 cm(2) VAT reduction in tesamorelin vs 2 +/- 35 cm(2) in placebo at 26 wk, P < 0.001.
A
grade
Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B/C and Chronic Kidney Disease: An Open-Label, Phase I Study.
Pasireotide · European journal of drug metabolism and pharmacokinetics · 2023 · RCT · Phase 1
Pasireotide shows rapid absorption and sustained release in male volunteers with chronic kidney disease and hepatitis B/C, but the clinical implications of these findings are not yet clear.
Maximal concentration at 0.5 h after SC injection(s) of pasireotide (300-900 µg).
B
grade
Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity.
LL-37 · Current eye research · 2005 · Observational
LL-37 is expressed in ocular surface epithelia and shows significant antibacterial and antiviral activity in vitro, but further research is needed to confirm its clinical relevance.
EC50 values for three strains of Pseudomonas aeruginosa were 2.8 +/- 1.3, 1.9 +/- 0.3, and 3.6 +/- 2.1 microg/ml.
B
grade
A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Leuprorelin · Breast cancer (Tokyo, Japan) · 2021 · Observational
Leuprorelin treatment for ≥3 years does not show a significant benefit over 2 years in overall disease-free survival for premenopausal breast cancer patients, but may offer advantages for higher-risk individuals.
HR 0.944, 95% CI 0.486-1.8392 for DFS between ≥3 years and 2 years.
Showing 25 of 841